{"url":"https://lda.senate.gov/api/v1/filings/4eeef76f-efd6-4f3e-8ab5-de2ea2149f6a/","filing_uuid":"4eeef76f-efd6-4f3e-8ab5-de2ea2149f6a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2012,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/4eeef76f-efd6-4f3e-8ab5-de2ea2149f6a/print/","filing_document_content_type":"text/html","income":null,"expenses":"115000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Heather Turner","dt_posted":"2012-07-19T11:57:33.177000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3344 North Torrey Pines Ct., Ste 200","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"La Jolla","registrant_state":"CA","registrant_zip":"92037","registrant":{"id":400744224,"url":"https://lda.senate.gov/api/v1/registrants/400744224/","house_registrant_id":null,"name":"OREXIGEN THERAPEUTICS, INC.","description":"A biopharmaceutical company focused on the treatment of obesity","address_1":"3344 North Torrey Pines Ct., Ste 200","address_2":null,"address_3":null,"address_4":null,"city":"La Jolla","state":"CA","state_display":"California","zip":"92037","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"HEATHER TURNER","contact_telephone":"+1 847-361-6719","dt_updated":"2022-04-06T16:08:13.569636-04:00"},"client":{"id":194824,"url":"https://lda.senate.gov/api/v1/clients/194824/","client_id":12,"name":"OREXIGEN THERAPEUTICS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-03-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the regulation of novel therapeutics for the treatment of obesity.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":56413,"prefix":"ms","prefix_display":"MS.","first_name":"HEATHER","nickname":null,"middle_name":"DINEEN","last_name":"TURNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57752,"prefix":"ms","prefix_display":"MS.","first_name":"SUZANNE","nickname":null,"middle_name":"MARIE","last_name":"MCDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":56404,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"KIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":56405,"prefix":null,"prefix_display":null,"first_name":"KEVIN","nickname":null,"middle_name":null,"last_name":"BRENNAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}